Preclinical characterization of a PD-1-CD28 fusion receptor in CD4+ T cells for T cell-based immunotherapy of pancreatic cancer and Non-Hodgkin Lymphoma

      Background: Interaction of the programmed death receptor 1 (PD1) and its ligand, PD-L1, has been shown to suppress T cell activity and allows tumors to evade T cell mediated immune-response. Our group recently showed that antigen-specific T cells transduced with a PD1-CD28 fusion receptor are protected from PD1-mediated inhibition. These cells are co-stimulated via CD28 signalling, resulting in tumor-rejections in a murine model of pancreatic cancer. The following study aims to proof the synergistic therapeutic effect of PD-1-CD28 fusion receptor transduced CD4+ and CD8+ T cells for immunotherapy of pancreatic cancer and Non-Hodgkin-Lymphoma.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect